Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...
Great. Good afternoon. Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference today with BioNTech. First, you're going to ...
BioNTech has increased its previous revenue guidance and now expects its revenues for the full 2025 financial year to be in the range of €2,600 - €2,800 million. With regards to COVID-19 vaccine ...
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking at the J.P. Morgan Healthcare Conference in San Francisco, ...
As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. The recent ...
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results